Active ingredient
Ceftazidime
10 finished FDA listings contain Ceftazidime as their only active ingredient; 1 combination products also contain it.
FDA NDC Directory
- Ingredient names as written by FDA
- CEFTAZIDIME
- Dosage forms
- Injection, Powder, For Solution
- Routes
- Intramuscular, Intravenous
- Manufacturers / labelers
- 3
- Strengths listed
- 1 g/1 · 2 g/1 · 6 g/1 · 6 g/30ml
- Brand names in FDA listings
- Tazicef
RxNorm (National Library of Medicine)
Ingredient concept RxCUI 2191
Drugs@FDA applications
Linked only where the FDA listing’s application number matches Drugs@FDA exactly. A listing in the NDC Directory does not by itself mean FDA approval.
| Application | Sponsor | Original approval | Listings |
|---|---|---|---|
| ANDA 062640 | ACS DOBFAR | 1985-11-20 | 6 |
| ANDA 062662 | HOSPIRA | 1986-03-06 | 3 |
| ANDA 064032 | HOSPIRA | 1993-10-31 | 1 |
Official labeling on DailyMed
- CEFTAZIDIME INJECTION, POWDER, FOR SOLUTION [SAGENT PHARMACEUTICALS] · version 12 · 2026-08-10
- TAZICEF (CEFTAZIDIME) INJECTION, POWDER, FOR SOLUTION [HOSPIRA, INC.] · version 30 · 2026-06-10
- TAZICEF (CEFTAZIDIME) INJECTION, POWDER, FOR SOLUTION [HOSPIRA, INC.] · version 16 · 2026-05-13
- TAZICEF (CEFTAZIDIME) INJECTION, POWDER, FOR SOLUTION [HOSPIRA, INC.] · version 30 · 2024-07-05
- CEFTAZIDIME INJECTION, POWDER, FOR SOLUTION [WG CRITICAL CARE, LLC] · version 10 · 2024-02-01
- CEFTAZIDIME INJECTION, POWDER, FOR SOLUTION [SAGENT PHARMACEUTICALS] · version 9 · 2024-01-05
Sources: FDA NDC Directory (2026-09-29), RxNorm, Drugs@FDA, DailyMed. Each source’s facts are shown separately as published.